Difference between revisions of "Vindesine (Eldisine)"
Jump to navigation
Jump to search
(Created page with "==General information== Class/mechanism: <ref name="insert">[**PUT PDF FILE HERE** Vindesine (Eldisine) package insert]</ref><ref>[http://hemonc.org/docs/packageinsert/vindesine....") |
|||
| Line 1: | Line 1: | ||
==General information== | ==General information== | ||
| − | Class/mechanism: <ref name="insert">[ | + | Class/mechanism: Vinca alkaloid, inhibits microtubule formation in the mitotic spindle, causing cell cycle arrest in metaphase.<ref name="insert">[http://www.bccancer.bc.ca/NR/rdonlyres/D6279B9B-2F71-4784-8AF8-D1452648635C/19507/Vindesinemonograph_3Nov07.pdf Vindesine (Eldisine) package insert]</ref><ref>[http://hemonc.org/docs/packageinsert/vindesine.pdf Vindesine (Eldisine) package insert (locally hosted backup)]</ref> |
| − | <br>Route: | + | <br>Route: IV |
| − | <br>Extravasation: | + | <br>Extravasation: [[vesicant]] |
| − | For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as [http://www.thomsonhc.com/home/dispatch Micromedex], [http://online.lexi.com/ Lexicomp], [http://www.utdol.com/online/content/search.do UpToDate (courtesy of Lexicomp)], or the | + | For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as [http://www.thomsonhc.com/home/dispatch Micromedex], [http://online.lexi.com/ Lexicomp], [http://www.utdol.com/online/content/search.do UpToDate (courtesy of Lexicomp)], or the prescribing information<ref name="insert"></ref>. |
==Patient drug information== | ==Patient drug information== | ||
| + | *[http://www.macmillan.org.uk/Cancerinformation/Cancertreatment/Treatmenttypes/Chemotherapy/Individualdrugs/Vindesine.aspx Macmillan Vindesine (Eldisine) patient information]<ref>[http://www.macmillan.org.uk/Cancerinformation/Cancertreatment/Treatmenttypes/Chemotherapy/Individualdrugs/Vindesine.aspx Macmillan Vindesine (Eldisine) patient information]</ref> | ||
*[http://www.uptodate.com/contents/vindesine-patient-drug-information Vindesine (Eldisine) patient drug information (UpToDate)]<ref>[http://www.uptodate.com/contents/vindesine-patient-drug-information Vindesine (Eldisine) patient drug information (UpToDate)]</ref> | *[http://www.uptodate.com/contents/vindesine-patient-drug-information Vindesine (Eldisine) patient drug information (UpToDate)]<ref>[http://www.uptodate.com/contents/vindesine-patient-drug-information Vindesine (Eldisine) patient drug information (UpToDate)]</ref> | ||
==References== | ==References== | ||
<references/> | <references/> | ||
Revision as of 01:30, 26 February 2012
General information
Class/mechanism: Vinca alkaloid, inhibits microtubule formation in the mitotic spindle, causing cell cycle arrest in metaphase.[1][2]
Route: IV
Extravasation: vesicant
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, UpToDate (courtesy of Lexicomp), or the prescribing information[1].
Patient drug information
- Macmillan Vindesine (Eldisine) patient information[3]
- Vindesine (Eldisine) patient drug information (UpToDate)[4]